Martyn Andrews was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
BioPharm America, to be held in Boston on September 5 and 6, 2018, will bring together startups, established companies and investors from the life sciences industry, as Kari Luu reports.
Manuel Salmeron-Sanchez and Matthew Dalby were selected in the LSIPR 50 2018 publication for their influence on the life sciences industry. They featured in the business and innovation section, as LSIPR reports.
Naoko Munakata was selected in the LSIPR 50 2018 publication for her influence on the life sciences industry. She featured in the government and policy section, as LSIPR reports.
Raymond Chen and Kathleen O’Malley were selected in the LSIPR 50 2018 publication for their influence on the life sciences industry. They featured in the government and policy section, as LSIPR reports.
Josh Makower, partner at venture capital investor New Enterprise Associates, explains to LSIPR the firm’s role in supporting medtech innovation, his sweet spot when it comes to projects, and how to balance what is medically relevant with commercial viability.
In the area of precision medicine, there are questions surrounding what data is needed, how it is used, what it should look like and what concerns there are for patients and society, as Daniel Lim of Kirkland & Ellis reports.
As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.
Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.
A lack of blood donors and poor healthcare infrastructure inspired Temie Giwa-Tubosun to develop and deliver a life-saving app. LSIPR spoke to the founder of LifeBank.